Polymorphic light eruption

Summary

Polymorphic light eruption (MONDO:0041182) is a disease and 10 clinical trials. Top therapeutic interventions include afamelanotide, cholecalciferol, and medium-chain triglycerides. A subtype of photosensitivity disease — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 10

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	polymorphic light eruption
Mondo ID	MONDO:0041182
ICD-10-CM	L56.4
ICD-11	1883086071
SNOMED CT	238525001
UMLS	C0031736
MedGen	508043
Is cancer (heuristic)	no

Also known as: polymorphic light eruption · polymorphous light eruption

Disease family

This is a subtype of photosensitivity disease. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › integumentary system disorder › skin disorder › dermatitis › radiodermatitis › photosensitivity disease › polymorphic light eruption

Related subtypes (3): skin sensitivity to sun, photoallergic dermatitis, phototoxic dermatitis

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 10.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	8
PHASE3	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01595893	PHASE3	TERMINATED	Vitamin D Supplementation in Polymorphic Light Eruption
NCT04704713	PHASE3	COMPLETED	Afamelanotide in Patients Suffering From Polymorphic Light Eruption (PLE)
NCT00472901	Not specified	COMPLETED	Phase III Trial of CUV1647 in Polymorphic Light Eruption (PLE)
NCT00549588	Not specified	COMPLETED	Sunscreen and After-sun-lotion Protection in Polymorphic Light Eruption
NCT00555178	Not specified	COMPLETED	Regulatory T Cells (Tregs) in Polymorphic Light Eruption
NCT00871052	Not specified	COMPLETED	Calcipotriol and Polymorphic Light Eruption
NCT03340155	Not specified	UNKNOWN	Mechanisms of Action of Photo(Chemo)Therapy in Skin Diseases
NCT04985526	Not specified	UNKNOWN	Skin Microbiome and Polymorphic Light Eruption
NCT05320315	Not specified	COMPLETED	Protective Effect Assessment of Foto Ultra Isdin Solar Allergy Fusion Fluid on the UVA Induced PLE
NCT05391178	Not specified	COMPLETED	Improving Disease Severity

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
AFAMELANOTIDE	4	2
CHOLECALCIFEROL	4	1
MEDIUM-CHAIN TRIGLYCERIDES	3	1
PROPANOL	-1	1